Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus KETOTIFEN FUMARATE.
CLARITIN HIVES RELIEF vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
10 mg orally once daily
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer